Abstract
Streptococcus pyogenes leads to 500,000 deaths annually; many due to rheumatic heart disease in low-income settings. Limited understanding of natural protective immunity to S. pyogenes hinders vaccine development. We describe the evolution of serological profiles to conserved vaccine-antigens and type-specific M peptides from birth and throughout the life course in The Gambia. As placentally-transferred IgG waned after birth, serological evidence of new exposure was seen in 23% infants during the first year of life. Following culture-confirmed S. pyogenes events, the highest IgG increases occurred in children under two years following both pharyngeal and skin disease, and asymptomatic carriage at both sites. Higher IgG to conserved antigens SLO, SpyCEP and SpyAD correlated with functional activity and were associated with protection from culture-confirmed events following adjustment for age and anti-M protein IgG levels. Our data provide the first evidence of protection associated with humoral immunity to conserved vaccine candidate antigens in humans.
Competing Interest Statement
AJK received training in immunoassay development and delivery from GSK Vaccines Institute for Global Health (GVGH), an affiliate of GSK. GSK had no role in overall study design, data analysis, nor data interpretation for this study. OR MC EB LR LM, MI, DGM are employees of GSK Vaccines. AB and PRS are inventors on a submitted patent related to Streptococcus pyogenes vaccines.
Funding Statement
The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The maternal vaccination cohort study was funded by the Meningitis Research Foundation. The household cohort study was funded by two Wellcome Trust Clinical PhD fellowships in Global Health awarded to AJK and EPA via London School of Hygiene & Tropical Medicine (award references 225467/Z/22/Z and 222927/Z/21/Z). Emm-typing was supported by the Fonds de la recherche Scientifique-FNRS (CDR J.0018.20 and PDR T.0227.20). GdeC is a Research Fellow of the Fonds de la Recherche Scientifique [ASP/A622]. This work was in part supported by BactiVac, the Bacterial Vaccines Network funded by the MRC and the International Science Partnerships Fund. Additional support was provided by The Department of Health and Social Care as part of the Global AMR Innovation Fund (GAMRIF), a UK aid programme that supports early-stage innovative research in underfunded areas of antimicrobial resistance (AMR) research and development for the benefit of those in low- and middle-income countries (LMICs), who bear the greatest burden of AMR. The views expressed in this publication are those of the author(s) and not necessarily those of the UK Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The studies received approval from the joint ethics committee of The Gambia Government/Medical Research Council and the London School of Hygiene & Tropical Medicine Research Ethics Committee (ref: 24005 and 1585). Written informed consent was obtained from adult participants, as well as from parents or guardians for participants under 18 years of age. Additionally, children aged 12 to 17 years provided assent. The studies are registered on ClinicalTrials.gov (NCT05117528 and NCT03746665).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All code to perform our analyses is currently publicly available and upon acceptance we will release de-identified primary data into the public domain as an open-access resource for the community.
